Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[Novel Assays, in press]
Novel Assays of GH/IGF-I: Bioactivity Clinical Correlations. Moderador: Martin Bidlingmaier, Klinikum der Univ Munchen.(Alemania).
[Frystyk, in press]
Kinase receptor activation (KIRA) assay assessment of IGF-I activity. J Frystyk.
[Bougneres, in press]
IGF-I Signaling in lymphocytes & assessment of GH sensitivity. P-F Bougneres.
[Hokken-Koelega, in press]
Free IGF-I compared to total IGF-I in the assessment of GH responsiveness. A Hokken-Koelega.
[Trainer, in press]
Options for the acromegalic patient following surgery. P Trainer.
[Webb, in press]
Quality of life assessment of the pituitary patient. SM Webb.
[Raymond Laws]
Radiosurgery for pituitary tumors: has it come of age?. E Raymond Laws.
[OR28-3]
Follow up GH levels but not IGF-I are useful in predicting mortality in acromegaly; however current targets for GH may be too high. M Sherlock, RC Reulen, A Aragon Alonso, J Ayuk, MM Hawkins, MC Sheppard, et al.
[OR28-4]
Outcome of transsphenoidal microsurgery in 209 patients with acromegaly. CR Ku, SH Kim, EJ Lee.
[OR03-1]
Real-time two-photon imaging of prolactin-cell network function. DJ Hodson, M Schaeffer, J Birkenstock, P Fontanaud, C Lafont, F Molino, et al.
[P1-151]
Ectopic acromegaly caused by a GHRH-secreting bronchial carcinoid tumor in a type 1 diabetic patient. PW Butler, CS Cochran, P Gorden.
[P1-595]
Growth hormone (GH) overexpression, but not GH injection is associated with increased serum aldosterone levels in mice.
[P1-662]
High-dose octreotide LAR is effective and safe in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy: a randomized, controlled trial. A Giustina, S Bonadonna, G Bugari, A Colao, R Cozzi, S Cannavo, et al.
[P1-663]
Does the cerebrospinal fluid mirror the silent hormones expressed by pituitary adenoma cells? MG Coculescu, ML Gheorghiu, C Badiu, A Caragheorgheopol, A Dumitrascu.
[P1-670]
Expression of somatostatin receptors subtypes in human pituitary adenomas, immunohistochemical studies. H Pisarek, M Pawlikowski, J Kunert-Radek, M Radek.
[P1-675]
Treatment outcomes of pituitary tumors at the University of Santo Tomas Hospital: 2004-2008. JS Fonte, EC Cunanan, BJ Matawaran, LB Mercado-Asis.
[P1-676]
Analysis of genetic variants of phosphodiesterase 11A (PDE11A) in acromegalic patients. E Peverelli, F Ermetici, M Filopanti, C Ronchi, S Ferrero, S Bosari, et al.
[P1-679]
Acromegaloidism or pseudoacromegaly: physical features with normal GH dynamics. a case report. A Lulsegged, M Bielohuby, M Kummann, J Manolopoulou, E Wolf, A Hoeflich, et al.
[P1-680]
A mother and daughter with somatotrophinomas familial or co-incidental? S Lim, MS Elston, JV Conaglen.
[P1-681]
Pituitary MRI negative acromegaly: is there a role for transphenoidal pituitary exploration? S Daud, M Hamaty, L Olansky.
[P1-682]
DIY Treatment of acromegaly. BM McGowan, DL Morganstein, ECI Hatfield, NM Martin, K Meeran.
[P1-683]
Two cases of severe acromegaly resistant to high doses of pegvisomant in combination with a somatostatin analog. E Morin, F Berthelet, J Lesage, M Bidlingmaier, O Serri.
[P1-689]
Marked growth hormone suppression during pregnancy in acromegaly. ML Dias, JGH Vieira, NR Musolino, J Abucham.
[P1-690]
Diminished and irregular TSH secretion with unchanged diurnal phase in active acromegaly. F Roelfsema, NR Biermasz, M Frolich, DM Keenan, JD Veldhuis, JA Romijn.
[P1-691]
Growth hormone administration reduces visceral adiposity and HsCRP in patients with growth hormone deficiency following cure of acromegaly: a randomized, placebo-controlled study. KK Miller, TL Wexler, P Fazeli, LE Gunnell, G Graham, BMK Biller, et al.
[P1-692]
Duration of exposure to high levels of circulating GH and IGF-I concentrations predict diverticular disease in patients with acromegaly; a case-control study. NR Biermasz, MJE Wassenaar, M Cazemier, AM Pereira Arias, F Roelfsema, JWA Smit, et al.
[P1-693]
Increased prevalence of gallbladder polyps in acromegalic subjects. EL Gayton, AK Annamalai, A Webb, C Rice, F Ibram, A Chaudhry, et al.
[P1-695]
Cross-sectional study of bone mineral density, hormonal parameters and body composition in 70 patients with acromegaly. TJ Reid, CA Navarro, CM Reyes-Vidal, PU Freda.
[P1-696]
Pre-treatment IGF-I concentrations predict radiographic osteoarthritis in acromegalic patients with long-term cured disease. NR Biermasz, MJE Wassenaar, AA Van der Klaauw, AM Pereira, JWA Smit, F Roelfsema, et al.
[P1-697]
The prevalence of abnormalities in glucose metabolism in newly diagnosed acromegalic patients: how it relates to disease activity and GH receptor genotype. AL Espinosa de los Monteros, G Vargas, B Gonzalez, M Mercado.
[P1-698]
Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly. A Bianchi, G Mazziotti, V Cimino, A Fusco, L Tartaglione, A D’Uonnolo, et al.
[P1-699]
Electrophysiological and neurocognitive impairment in patients with active acromegaly. J León-Carrión, JF Martín-Rodríguez, A Madrazo-Atutxa, E Torres-Vela, P Benito-López, A Soto-Moreno, et al.
[P1-700]
Direct measurement of muscle sympathetic nerve activity in acromegaly. evidence for a decreased adrenergic tone. C Carzaniga, G Seravalle, L Lonati, R Attanasio, R Cozzi, L Fatti, et al.
[P1-701]
Impact of metabolic factors on IGF-1 levels in treated acromegalic patients with divergent GH/IGF-1 level. M Matta, V Bongard, S Grunenwald, J-C Maiza, A Bennet, P Caron.
[P1-703]
Incidence of benign and malignant tumours in acromegalic patients studied at one centre. A Baldys-Waligorska, F Golkowski, A Krzentowska, G Sokolowski, A Hubalewska-Dydejczyk.
[P1-704]
The relationship between serum ghrelin levels and the disturbances of lipid profile in patients with acromegaly. MA Jaskula, R Wasko, H Komarowska, M Bolanowski, J Sowinski.
[P1-705]
Relation with early atherosclerosis and procalcitonin in active and inactive acromegalic patients. H Ozkan, O Celik, F Kantarci, P Kadioglu.
[P1-706]
High prevalence of active disease in patients formerly treated for acromegaly. JC Piswanger-Solkner, C Cimenti, R Maier, J Gerdova, A Fahrleitner-Pammer, R Rienmuller, et al.
[P1-707]
The estimated glomerular filtration rate (GFR) is elevated in patients with acromegaly. Y Yamakado, M Kurimoto, N Hizuka, J Morita, S Tanaka, I Fukuda, et al.
[P1-708]
The clinical features and therapeutic outcomes in 110 patients with acromegaly at a single institute. I Fukuda, N Hizuka, M Kurimoto, J Morita, S Tanaka, Y Yamakado, et al.
[P1-709]
Trigger finger, an early musculoskeletal manifestation of acromegaly. E Resmini, A Tagliafico, MT van Holsbeeck, C Martinoli, L Derchi, F Minuto, et al.
[P1-710]
No increase in aortic diameters in patients with acromegaly in comparison to epidemiological data from the general population of the Heinz-Nixdorf-Recall (HNR) study. CA Berg, H Kaelsch, BL Herrmann, H Lahner, H Eggebrecht, M Broecker- Preuss, et al; on Behalf of the Investigative Group of the Heinz Nixdorf Recall Study.
[P1-711]
Malignancy investigation in acromegalic patients. B Esen Gullu, O Celik, P Kadioglu.
[P1-712]
Phenomenon of limiting GH stimulation of IGF-1 secretion in acromegalic patients. AVD Dreval, JGP Pokramovich, O Nechaeva.
[P1-713]
Russian register of patients with acromegaly. IA Ilovayskaya, NN Molitvoslovova, OY Egorova, EG Przheolkovskaya, VS Pronin, LY Rozhinskaya, et al.
[P1-714]
Recent epidemiology of acromegaly in korea. O Kwon, EY Park, EJ Lee, YD Song, SY Kim; Rare Disease Study Group.
[P1-715]
Elastographic evaluation of thyroid nodules in acromegaly. M Andrioli, C Carzaniga, G Vitale, M Moro, L Poggi, L Fatti, et al.
[P1-716]
Thyroid autoimmune disorders in acromegaly. M Manavela, A Juri, K Danilowicz, L Miechi, V Fernandez Valoni, OD Bruno.
[P1-717]
Assessment of somatic mutation in growth hormone receptor codon 49 in human somatotroph adenomas. JA Evang, SL Fougner, JP Berg, J Bollerslev.
[P2-168]
Combined application of octreotide and pasireotide (SOM230) prevents hyperglycemia and escape of IGF-1 inhibition in rats. HA Schmid.
[P2-736]
Urine albumin excretion is normal in growth hormone (GH) deficient adults but decreases after GH replacement. CRP Oliveira, JAS Barreto-Filho, RA Meneguz-Moreno, R Salvatori, VP Araujo, RMC Pereira, et al.
[P3-134]
Associations between plasma insulin-like growth factor i and the markers of inflammation interleukin 6, C-reactive protein and YKL-40 in an elderly normal population. M Andreassen, I Raymond, P Hildebrandt, C Kistorp, C Rathcke, H Vestergaard, et al.
[P3-138]
IGF1 levels in patients with liver steatosis. S Mallea-Gil, C Ballarino, K Bertini, C Ridruejo, MM Aparicio, O Villanueva, et al.
[P3-650]
Unique clinicopathological appearance of lymphocytic hypophysitis in a young male presenting with elevated serum IGF-1. C Chadha, ER Seaquist.
[P3-673]
A Phase II exploratory study of BIM23A760 in acromegalic patients: preliminary results of safety and efficacy after a single-dose administration. C Lesage, C Seymour, V Urbanavicius, A Beckers, G Kazanavicius, A Colao.
[P3-674]
Predictors of somatostatin analog effects on glucose metabolism in acromegaly: a meta-regression analysis. G Mazziotti, I Floriani, S Bonadonna, V Torri, P Chanson, A Giustina.
[P3-675]
Pharmacokinetic and pharmacodynamic response to a 6-month octreotide hydron implant in patients with acromegaly. P Kuzma, H Quandt, C Childs, M Harnett, S Decker, M Ryan, et al.
[P3-676]
AIP immunostaining is increased with lanreotide therapy in individuals with acromegaly and predicts changes in IGF-1 levels in female patients. HS Chahal, O Ansorge, N Karavitaki, E Carlsen, JAH Wass, AB Grossman, et al.
[P3-677]
Pasireotide (SOM230) provides biochemical control in patients with active acromegaly: pharmacokinetic/pharmacodynamic (PK/PD) results from a randomized, multicenter, phase II trial. K Hu, Y Zhang, J Jung, A Buchelt, Y Wang, S Petersenn.
[P3-678]
The acromegalic cardiovascular and respiratory outcomes with primary analogue therapy (A.C.R.O.P.A.T.) trial. A Webb, EL Gayton, AK Annamalai, S Pilsworth, S O’Toole, S Ariyaratnam, et al.
[P3-679]
Changes in insulin sensitivity, pancreatic beta cell function and tissue markers of insulin action in newly diagnosed acromegalic subjects treated with primary medical (somatuline autogel) therapy. EL Gayton, AK Annamalai, A Webb, S Ariyaratnam, S O’Toole, A Chaudhry, et al.
[P3-680]
Study of administration interval of octreotide LAR in the treatment of acromegaly. C Shimizu, M Yoshida, S Nagai, N Yoshioka, T Koike, K Matsuno.
[P3-681]
Oral glucose tolerance test (OGTT) after pretreatment with octreotide 100 mcg s.c. (SHort Octreotide Test SHOT) do not predict glucose intolerance during prolonged treatment with octreotide LAR. P Zdunowski, W Zgliczynski.
[P3-682]
Effectiveness of self- or partner-administration of an extended-release aqueous-gel formulation of lanreotide in patients with acromegaly. R Salvatori, L Nachtigall, D Cook, V Bonert, M Molitch, S Blethen, et al.
[P3-683]
Prevalence of cardiac valve regurgitation in acromegalic patients treated with cabergoline. RS Jallad, FH Duarte, MD Bronstein.
[P3-684]
A prospective clinical trial of combined cabergoline (C) and pegvisomant (pegV) treatment in patients with active acromegaly. CE Higham, AB Atkinson, S Alywin, NM Martin, V Moyes, J Newell-Price, et al.
[P3-686]
Prospective study to assess impact of pegvisomant combined with octreotide on disease control and glucose metabolism in acromegalic subjects. P Zdunowski, W Zgliczynski.
[p3-687]
Reversible pegvisomant-related lypohypertrophy and its possible recurrence at the new site of injection: a clinical and radiological outcome in two acromegalic women. V Rochira, L Zirilli, S Romano, G Brigante, C Carani.
[P3-688]
A 4-month treatment with lanreotide autogel 120 mg can normalize IGF-I levels in over one third of acromegalic patients previously treated by pegvisomant. P Birman, C Lesage, M-E Fages, C Seymour, A-J Van Der Lelij.
[P3-689]
Change in (NT Pro) BNP and body weight are possible markers for improved quality of life after the addition of pegvisomant, in controlled acromegaly patients during long term somatostatin analog treatment. SJCMM Neggers, WW Herder, JAMJL Janssen, RA Feelders, AJ van der Lely.
[P3-690]
Serum retinol-binding protein 4 and adiponectin levels in acromegaly: evidence for reduction in retinol-binding protein 4 levels following surgical treatment of growth hormone excess. C Christodoulides, K Burling, V Fazal-Sanderson, N Karavitaki, JAH Wass.
[P3-691]
Impact of different previous treatments on the prevalence of growth hormone deficiency (GHD) in cured acromegalic patients. CL Ronchi, C Giavoli, E Ferrante, E Verrua, S Bergamaschi, DI Ferrari, et al.
[P3-692]
Endoscopic transsphenoidal pituitary surgery in forty patients with a growth hormone secreting macroadenoma. MAEM Wagenmakers, RT Netea-Maier, EJ van Lindert, GF Pieters, JA Grotenhuis, ARMM Hermus.
[P3-693]
High E-cadherin levels in the acute octreotide responsive, the small and the less invasive somatotroph adenomas. SL Fougner, J Bollerslev, JK Hald, J Ramm-Pettersen, O Casar Borota, JP Berg.
[P3-694]
Somatic aryl hydrocarbon receptor interacting protein mutations are absent in sporadic somatotropinomas and in familial prolactinoma. BS Soares, EO Hansen, EP Dias, LA De Marco, MS Sarquis.
[P1-678]
Increased prevalence of autoimmune diseases in patients with prolactinomas. P Cassidy, H Al Humrani, N Garfield, J Rivera.
[P3-630]
Apparently sporadic pituitary adenomas presenting in children and young adults are rarely caused by mutations in the MEN1 gene. SG Waguespack, IE McCutcheon, JK Devin, DB Evans, G Cote, T Rich.
[P3-634]
The influence of other hormonal disturbances on the bone density and turnover in women with hyperprolactinemia of various origin. M Bolanowski, B Zadrozna-Sliwka, A Jawiarczyk, J Syrycka.
[P3-654]
Prolactin (PRL)-secreting pituitary atypical adenoma: cyber knife radiosurgery induced tumor shrinkage and normalization of PRL level. S Shimazu, A Shimatsu, T Usui, S Yamada, K Sato, T Tagami, et al.
[P3-657]
Giant prolactinoma mimicking a skull base tumor causing hypoacusia and nasal obstruction. ES Portugal-e-Silva, CB Formiga-Bueno, A Glezer, DB Paraiba, MD Bronstein.
[P3-658]
Long term management of erosive prolactinoma with low dose cabergoline: a case report. ND Stojanovic, P Kelly, FM Nkonge, S Chawda, J Benjamin.
[P3-659]
A case of prolactinoma with concomitant posterior pituitary microadenoma. PN Surampudi, J Waddadar, V Rodina, AK Pandey, JJ Kalarickal, T Thethi.
[P3-660]
Clomiphene citrate effects on male patients with treated macroprolactinoma and persistent hypogonadism. CB Formiga-Bueno, ES Portugal-e-Silva, DB Paraiba, A Glezer, MD Bronstein.
[P3-661]
A case of breast cancer in a patient with prolactinoma. JD FitzGerald, CL Chik.
[P3-694]
Somatic aryl hydrocarbon receptor interacting protein mutations are absent in sporadic somatotropinomas and in familial prolactinoma. BS Soares, EO Hansen, EP Dias, LA De Marco, MS Sarquis.
[P3-695]
Effects of dopamine agonists on growth hormone secretion in prolactinoma patients. J Ullal, DW Richardson.
[P3-708]
Pituitary adenoma in children and adolescents. P Katavetin, P Cheunsuchon, M Misra, B Swearingen, ET Hedley-Whyte, LL Levitsky.
Copyright © 2010. Sociedad Española de Endocrinología y Nutrición
